Sphingosine 1-phosphate (S1P) induces S1P2 receptor-dependent tonic contraction in murine iliac lymph vessels

Microcirculation. 2013 Jan;20(1):1-16. doi: 10.1111/micc.12001.

Abstract

Objective: We studied the effects of S1P on the diameter and spontaneous contraction of murine iliac collecting lymph vessels.

Methods: The isolated lymph vessel was cannulated with two glass micropipettes and then pressurized to 4 cmH(2) O at the intraluminal pressure. The changes in lymph vessel diameter were measured using a custom-made diameter-detection device. Immunohistochemical studies were also performed to confirm S1P receptors on the lymph vessels.

Results: S1P (10(-7) M) had no significant effect on the frequency or amplitude of the lymph vessels' spontaneous contractions. In contrast, S1P (10(-8) -10(-6) M) produced a concentration-related reduction in lymph vessel diameter (tonic contraction). Pretreatment with 10(-4) M l-NAME or 10(-5) M aspirin had no significant effect on the S1P-induced tonic contraction of the lymph vessels. To evaluate the intracellular signal transduction pathway responsible for the S1P-induced tonic contractions and their Ca(2+) -dependence, we investigated the effects of JTE013, VPC23019, U-73122, xestospongin C, and nifedipine on the S1P-induced tonic contractions. All of these inhibitors except VPC23019 and nifedipine significantly reduced the S1P-induced tonic contractions. S1P (5x10(-7) M) also induced significant tonic contractions in the lymph vessels that had been superfused with high K(+) Krebs-bicarbonate solution or Ca(2+) -free high K(+) Krebs solution containing 1 mM EGTA. S1P2 receptors were immunohistochemically detected in the lymph vessels.

Conclusion: These findings suggest that neither endogenous NO nor prostaglandins are involved in the S1P-induced tonic contraction of lymph vessels, which is mainly caused by Ca(2+) release from intracellular Ca(2+) stores through the activation of S1P2 and 1,4,5 IP(3) receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aspirin / pharmacology
  • Biomechanical Phenomena
  • Calcium Signaling / drug effects
  • Endothelium, Lymphatic / drug effects
  • Endothelium, Lymphatic / physiology
  • Estrenes / pharmacology
  • Lymphatic Vessels / drug effects*
  • Lymphatic Vessels / physiology*
  • Lysophospholipids / pharmacology*
  • Macrocyclic Compounds / pharmacology
  • Male
  • Mice
  • Muscle Contraction / drug effects
  • Muscle Contraction / physiology
  • Muscle, Smooth / drug effects
  • Muscle, Smooth / physiology
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nifedipine / pharmacology
  • Nitric Oxide / physiology
  • Oxazoles / pharmacology
  • Pressure
  • Pyrazoles / pharmacology
  • Pyridines / pharmacology
  • Pyrrolidinones / pharmacology
  • Receptors, Lysosphingolipid / antagonists & inhibitors
  • Receptors, Lysosphingolipid / physiology*
  • Signal Transduction / drug effects
  • Sphingosine / analogs & derivatives*
  • Sphingosine / pharmacology

Substances

  • Estrenes
  • JTE 013
  • Lysophospholipids
  • Macrocyclic Compounds
  • Oxazoles
  • Pyrazoles
  • Pyridines
  • Pyrrolidinones
  • Receptors, Lysosphingolipid
  • xestospongin C
  • 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
  • sphingosine 1-phosphate
  • Nitric Oxide
  • Nifedipine
  • Sphingosine
  • Aspirin
  • NG-Nitroarginine Methyl Ester